Back to All Collaborations

Celgene DNDi Partnership

Active Since: 2011

Contributing to SDGs…

Identifying and optimizing new drug candidates for the treatment of neglected tropical diseases (NTDs).



  • Academia or research institute

    Drugs for Neglected Diseases initiative (DNDi)

  • Global NGOs

    Drugs for Neglected Diseases initiative (DNDi)


  • The partnership aims to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs).

Partnership activities and how they address needs and challenges

Since 2011, Celgene Global Health (CGH) and DNDi have collaborated on the screening of CGH’s compound library for activity against NTDs.

In 2014, this collaboration was expanded towards the identification and optimization of potential therapeutic candidates for several of the world’s most neglected diseases, including leishmaniasis, sleeping sickness, Chagas disease, river blindness, and elephantiasis.

The Research Collaboration Agreement established between the two partners focuses on the lead optimization stage of research, with CGH providing novel compounds of interest for the targeted diseases and using its target-identification and drug-discovery technology platforms to progress these compounds up to identification of clinical candidates. DNDi will take the lead on hit confirmation and coordinate and conduct hit expansion, hit-to-lead compound work, and subsequent lead optimization work.

The agreement ensures that the result of the joint research enables DNDi to operate within the scope of neglected communicable diseases and in all endemic countries without the need to pay royalties or license fees. Celgene has the right of first negotiation to become DNDi’s clinical development, manufacture and distribution partner and commits to support broad access to patients in need in endemic countries.

In June 2016, Celgene became the fifth company to join the ‘Negelcted Tropicla Diseases Drug Discovery Booster’ consortium, an initiative set up one year before that aims to accelerate and cut the cost of early stage drug discovery for leishmaniosis and Chagas disease.

"The expertise Celgene has developed over the past years with its global health focus will be a great asset to drug discovery for neglected tropical diseases"
Dr Bernard Pcoul
Executive Director of DNDi


SDG 3: Good Health and Wellbeing

  1. 3.3: Communicable Diseases & NTDs

SDG 9: Industry Innovation and Infrastructure

SDG 17: Partnerships for the Goals